...Awesome. As am I. Why don't we start off with -- and I think this is probably where I get the most questions and what we're working on. So CRC, obviously, you're going against regorafenib, not particularly the best -- it's a good comparator to go against. It's a very tough disease. Obviously, on the Q1 call, the dual endpoint changes, I think a question people have. And the way I kind of see it is a company generally does not split their alpha if they're worried about the powering for their trial. But then you also have kind of two distinct populations, liver mets and non-liver mets, that might have two different event rates. So it's a bit complicated, I think, for investors to understand. I'd hand it off to you, Andrew. How should we think about that dual endpoint change? Is that a sign of confidence? Is that a sign of speed? Is that a sign of -- well, we want to put this drug in the best position to be [static] and we might be concerned about powering in certain populations? Andrew Peters...
